Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
2000 1
2002 1
2003 4
2004 2
2005 3
2006 4
2007 18
2008 32
2009 32
2010 44
2011 60
2012 82
2013 85
2014 87
2015 84
2016 100
2017 90
2018 93
2019 101
2020 107
2021 104
2022 68
2023 79
2024 43

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,166 results

Results by year

Filters applied: . Clear all
Page 1
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. Mesa RA, et al. J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20. J Clin Oncol. 2017. PMID: 28930494 Free PMC article. Clinical Trial.
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA. Harrison CN, et al. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32198525 Free PMC article. Review.
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Mascarenhas J, et al. JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818. JAMA Oncol. 2018. PMID: 29522138 Free PMC article. Clinical Trial.
Approach to MPN Symptom Assessment.
Geyer H, Mesa RA. Geyer H, et al. Curr Hematol Malig Rep. 2017 Oct;12(5):381-388. doi: 10.1007/s11899-017-0399-5. Curr Hematol Malig Rep. 2017. PMID: 28942516 Free PMC article. Review.
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
Curigliano G, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, Sarantopoulos J, Bedard PL, Lin CC, Hodi FS, Wilgenhof S, Santoro A, Sabatos-Peyton CA, Longmire TA, Xyrafas A, Sun H, Gutzwiller S, Manenti L, Naing A. Curigliano G, et al. Clin Cancer Res. 2021 Jul 1;27(13):3620-3629. doi: 10.1158/1078-0432.CCR-20-4746. Epub 2021 Apr 21. Clin Cancer Res. 2021. PMID: 33883177 Free article. Clinical Trial.
Allogeneic Stem Cell Transplantation in Myelofibrosis.
Jain T, Mesa RA, Palmer JM. Jain T, et al. Biol Blood Marrow Transplant. 2017 Sep;23(9):1429-1436. doi: 10.1016/j.bbmt.2017.05.007. Epub 2017 May 10. Biol Blood Marrow Transplant. 2017. PMID: 28499938 Free PMC article. Review.
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA. Harrison CN, et al. Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8. Lancet Haematol. 2017. PMID: 28602585 Free PMC article. Clinical Trial.
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA. Harrison CN, et al. Am J Hematol. 2020 Jun;95(6):594-603. doi: 10.1002/ajh.25777. Epub 2020 Apr 17. Am J Hematol. 2020. PMID: 32129512 Free PMC article. Clinical Trial.
Fedratinib in myelofibrosis.
Mullally A, Hood J, Harrison C, Mesa R. Mullally A, et al. Blood Adv. 2020 Apr 28;4(8):1792-1800. doi: 10.1182/bloodadvances.2019000954. Blood Adv. 2020. PMID: 32343799 Free PMC article.
1,166 results